Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
-
REGULATORY Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
-
BUSINESS Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
-
BUSINESS Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
-
BUSINESS Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
-
BUSINESS Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
-
REGULATORY Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
-
BUSINESS Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
-
REGULATORY Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
-
BUSINESS Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
-
BUSINESS With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
-
REGULATORY CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
-
ORGANIZATION Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
-
ORGANIZATION 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
-
REGULATORY MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
-
BUSINESS Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
-
BUSINESS CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
-
REGULATORY FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
-
ORGANIZATION IGPA Annual Conference to Adopt Kyoto Declaration including Int’l Harmonization on Generic Evaluation Criteria
November 28, 2012
-
BUSINESS Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…